GeoVax Labs, Inc. Warrants - GOVXW STOCK NEWS

Welcome to our dedicated page for GeoVax Labs Warrants news (Ticker: GOVXW), a resource for investors and traders seeking the latest updates and insights on GeoVax Labs Warrants stock.

GeoVax Labs, Inc. (OTCQB: GOVX) is a clinical-stage biotechnology company specializing in developing human vaccines and immunotherapies against infectious diseases and solid tumor cancers.

Utilizing novel proprietary platforms like the modified vaccinia ankara - virus-like particle (MVA-VLP) vaccine platform, GeoVax's pipeline includes ongoing human clinical trials for a next-generation COVID-19 vaccine and gene-directed therapy for head and neck cancers.

Additional research programs focus on preventive vaccines against infectious diseases like Monkeypox, hemorrhagic fever viruses (Ebola Zaire, Ebola Sudan, Marburg, and Lassa), and Zika virus, along with immunotherapies for various solid tumors.

Recent achievements include positive initial safety and immune response findings from a Phase 2 clinical trial evaluating GEO-CM04S1, the COVID-19 vaccine, as a heterologous booster in 63 healthy adults who previously received the Pfizer or Moderna mRNA vaccine. The trial has demonstrated statistically significant increases in neutralizing antibody responses against multiple SARS-CoV-2 variants.

09/26/2023 09:00 AM

News

GeoVax Secures Multi-Product License for ProBioGen's AGE1.CR.pIX® Suspension Cell Line to Bolster MVA-Based Vaccine Development

Rhea-AI Summary

GeoVax Labs and ProBioGen sign a commercial license agreement for ProBioGen's AGE1.CR.pIX suspension cell line, enhancing GeoVax's vaccine manufacturing capabilities. The cell line enables high-yield and scalable production, leading to cost-effectiveness and increased productivity. It supports a wide range of viruses and vaccine types, improving suitability for various vaccines in development. The partnership aims to accelerate vaccine production and distribution, benefiting communities worldwide.

Rhea-AI Impact

Rhea-AI Sentiment

End-of-Day

-- %

Tags

09/20/2023 09:00 AM

News

GeoVax Next-Generation COVID-19 Vaccine Data Presented at Keystone Symposia Conference

Rhea-AI Summary

Preclinical data for GEO-CM02 demonstrates single-dose protection against multiple SARS-CoV-2 variants. GEO-CM02 vaccine induces immune responses against original Wuhan strain and Omicron variant. Vaccine significantly reduces inflammation and immunopathology in vaccinated animals' lungs. Vaccines designed to induce both antibodies and T-cells can address viral variation and escape. GeoVax evaluating similar vaccine design in three Phase 2 clinical trials.

Rhea-AI Impact

Rhea-AI Sentiment

End-of-Day

-3.72%

Tags

09/19/2023 09:00 AM

News

GeoVax Next-Generation COVID-19 Vaccine Demonstrates Potent Antibody and Cellular Immunity in Immunocompromised Patients

Rhea-AI Summary

GeoVax Labs, Inc. publishes data from Phase 2 trial of GEO-CM04S1 COVID-19 vaccine, showing high immunogenicity in immunocompromised patients.

Rhea-AI Impact

Rhea-AI Sentiment

End-of-Day

-0.37%

Tags

09/12/2023 09:00 AM

News

GeoVax Presents Corporate Update at the H.C. Wainwright 25th Annual Global Investment Conference

Rhea-AI Summary

GeoVax Labs, Inc. presents updates on Gedeptin® and GEO-CM04S1 Phase 2 clinical trials

Rhea-AI Impact

Rhea-AI Sentiment

End-of-Day

-0.36%

Tags

09/11/2023 09:00 AM

News

GeoVax Completes Enrollment of Phase 2 Trial for Next-Generation COVID-19 Vaccine Booster

Rhea-AI Summary

GeoVax Labs completes enrollment target for Phase 2 clinical trial of GEO-CM04S1 as a COVID-19 vaccine booster

Rhea-AI Impact

Rhea-AI Sentiment

End-of-Day

-2.63%

Tags

08/31/2023 09:00 AM

News

GeoVax to Present at the H.C. Wainwright 25th Annual Global Investment Conference

Rhea-AI Summary

GeoVax Labs to provide updates on multiple Phase 2 clinical trials for GEO-CM04S1 and Gedeptin® during H.C. Wainwright conference.

Rhea-AI Impact

Rhea-AI Sentiment

End-of-Day

-4.94%

Tags

08/29/2023 09:00 AM

News

GeoVax to Present at the Emerging Growth Conference on September 6, 2023

Rhea-AI Summary

GeoVax Labs to provide updates on multiple phase 2 clinical trials for its COVID-19 vaccine and cancer immunotherapy programs at the Emerging Growth Conference on September 6, 2023.

Rhea-AI Impact

Rhea-AI Sentiment

End-of-Day

0.52%

Tags

08/28/2023 09:00 AM

News

GeoVax Receives Notice of Allowance for Malaria Vaccine Patent

Rhea-AI Summary

GeoVax Labs, Inc. receives patent allowance for a vaccine to treat or prevent malaria, covering compositions and methods for inducing an immune response. The vaccine incorporates antigens from multiple stages of the malaria parasite's life cycle, aiming to provide substantial protection. The company's development priorities remain focused on their next-generation COVID-19 vaccine and cancer immunotherapy program.

Rhea-AI Impact

Rhea-AI Sentiment

End-of-Day

3.57%

Tags

08/10/2023 09:00 AM

News

GeoVax Announces First Patients Vaccinated in Phase 2 Clinical Trial of COVID-19 Vaccine Booster in Patients with Chronic Lymphocytic Leukemia

Rhea-AI Summary

Rhea-AI Impact

Rhea-AI Sentiment

End-of-Day

-0.72%

Tags

08/09/2023 04:00 PM

News

GeoVax Reports 2023 Second Quarter Financial Results and Provides Corporate Update

Rhea-AI Summary

GeoVax Labs, Inc. (GOVX) Announces Progress and Promising Outlook for Gedeptin® and GEO-CM04S1; Phase 2 GEO-CM04S1 Clinical Trial Initiated for Patients with Chronic Lymphocytic Leukemia

Rhea-AI Impact

Rhea-AI Sentiment

End-of-Day

-0.72%

Tags

FAQ

What is the current stock price of GeoVax Labs Warrants (GOVXW)?

The current stock price of GeoVax Labs Warrants (GOVXW) is $0.1209 as of November 22, 2024.

What is GeoVax Labs, Inc. focused on developing?

GeoVax Labs, Inc. is focused on developing human vaccines and immunotherapies for infectious diseases and solid tumor cancers using innovative proprietary platforms.

What recent achievements has GeoVax Labs, Inc. made?

GeoVax Labs, Inc. achieved positive initial safety and immune response findings in a Phase 2 clinical trial for its COVID-19 vaccine.

Which diseases are targeted by GeoVax's vaccine development programs?

GeoVax targets infectious diseases like Monkeypox, hemorrhagic fever viruses (Ebola Zaire, Ebola Sudan, Marburg, and Lassa), Zika virus, along with developing immunotherapies for various solid tumors.